2024
Targetable ERBB2/HER2 Mutations in Gynecologic Malignancies: Clinicopathological, Immunohistochemical, and Molecular Correlations.
Manrai P, McHenry A, Sun T, Santin A, Ratner E, Lin D, Elvin J, Hui P, Buza N. Targetable ERBB2/HER2 Mutations in Gynecologic Malignancies: Clinicopathological, Immunohistochemical, and Molecular Correlations. International Journal Of Gynecological Pathology 2024 PMID: 38914011, DOI: 10.1097/pgp.0000000000001050.Peer-Reviewed Original ResearchEndometrial carcinomaGynecologic malignanciesTyrosine kinase domainHER2-mutated non-small cell lung cancerTargeted anti-HER2 therapyNon-small cell lung cancerHigh-grade endometrioid adenocarcinomasFam-trastuzumab deruxtecanOvarian mucinous adenocarcinomaAnti-HER2 therapyAnti-HER2 drugsHER2 3+US Food and Drug AdministrationCell lung cancerEndometrial serous carcinomaSolid tumor typesStandard treatment recommendationsFood and Drug AdministrationFluorescence in situ hybridizationGynecological cancer typesEndometrial primaryMullerian originSerous carcinomaHER2 IHCEndometrioid adenocarcinoma
2017
Comprehensive Analysis of PAX8 Expression in Epithelial Malignancies of the Uterine Cervix
Wong S, Hong W, Hui P, Buza N. Comprehensive Analysis of PAX8 Expression in Epithelial Malignancies of the Uterine Cervix. International Journal Of Gynecological Pathology 2017, 36: 101-106. PMID: 27362905, DOI: 10.1097/pgp.0000000000000309.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaEpithelial malignanciesPAX8 expressionAdenosquamous carcinomaMajority of SCCsCervical squamous cell carcinomaPossible primary sitesEndometrioid-type tumorsWeak nuclear stainingTissue microarray slidesGynecologic malignanciesEndometrial adenocarcinomaEndometrioid adenocarcinomaMetastatic lesionsEndometrial carcinomaMetastatic sitesUterine cervixCell carcinomaCervical tumorsEndocervical adenocarcinomaDifferential diagnosisPrimary siteAdenocarcinomaCarcinomaMalignancy